Open AccessComparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis
Author(s) -
Susanna Brauner,
Ann ErikssonDufva,
Max Albert Hietala,
Thomas Frisell,
Rayomand Press,
Fredrik Piehl
Publication year - 2020
Publication title -
jama neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.298
H-Index - 231
eISSN - 2168-6157
pISSN - 2168-6149
DOI - 10.1001/jamaneurol.2020.0851
Subject(s) - myasthenia gravis , rituximab , refractory (planetary science) , medicine , immunology , pediatrics , antibody , biology , astrobiology
Use of biologic agents in generalized myasthenia gravis is generally limited to therapy-refractory cases; benefit in new-onset disease is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom